Article info

Download PDFPDF

1389 GIGA-564 a third generation anti CTLA 4 with minimal ability to block CTLA 4 binding to B7 ligands has enhanced efficacy but reduced toxicity compared to ipilimumab in preclinical models
Free

Authors

Citation

Stone E, Carter K, Wagner E, et al
1389 GIGA-564 a third generation anti CTLA 4 with minimal ability to block CTLA 4 binding to B7 ligands has enhanced efficacy but reduced toxicity compared to ipilimumab in preclinical models

Publication history

  • First published November 7, 2022.
Online issue publication 
November 07, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.